Maneka Mirchandaney
Stock Analyst at Evercore ISI Group
(0.24)
# 4,050
Out of 4,712 analysts
8
Total ratings
25%
Success rate
-33.56%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Maneka Mirchandaney
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRNX Crinetics Pharmaceuticals | Maintains: Outperform | $41 → $48 | $53.96 | -11.05% | 2 | Sep 11, 2023 | |
| INKT MiNK Therapeutics | Maintains: Outperform | $4 → $3 | $0.49 | +510.75% | 2 | Mar 22, 2023 | |
| INCY Incyte | Downgrades: In-Line | $90 → $78 | $69.84 | +11.68% | 1 | Aug 3, 2022 | |
| BNOX Bionomics | Initiates: Outperform | $17 | $0.25 | +6,616.71% | 1 | Jan 10, 2022 | |
| VRDN Viridian Therapeutics | Initiates: Outperform | $40 | $19.67 | +103.36% | 1 | Oct 12, 2021 | |
| HOWL Werewolf Therapeutics | Initiates: Outperform | $23 | $1.57 | +1,364.97% | 1 | May 25, 2021 |
Crinetics Pharmaceuticals
Sep 11, 2023
Maintains: Outperform
Price Target: $41 → $48
Current: $53.96
Upside: -11.05%
MiNK Therapeutics
Mar 22, 2023
Maintains: Outperform
Price Target: $4 → $3
Current: $0.49
Upside: +510.75%
Incyte
Aug 3, 2022
Downgrades: In-Line
Price Target: $90 → $78
Current: $69.84
Upside: +11.68%
Bionomics
Jan 10, 2022
Initiates: Outperform
Price Target: $17
Current: $0.25
Upside: +6,616.71%
Viridian Therapeutics
Oct 12, 2021
Initiates: Outperform
Price Target: $40
Current: $19.67
Upside: +103.36%
Werewolf Therapeutics
May 25, 2021
Initiates: Outperform
Price Target: $23
Current: $1.57
Upside: +1,364.97%